Alerta

SYSTEM FOR MINIMIZING RISK OF TRANSMISSION OF INFECTION

Resumen de: US20260274133A1

Disclosed herein are systems for minimizing the risk of transmission of SARS-COV-2 and/or other infectious diseases between individuals in close proximity to one another. Said systems may comprise a substantially transparent shield component, a chamber component, and a suctioning component. The systems of the present disclosure are intended to remove any SARS-COV-2 virus and/or other infectious agents that may be travelling within aerosols.

LIPOSOME, ESPECIALLY FOR USE IN THE TREATMENT OF COVID-19

Resumen de: WO2022098250A1

An object of the invention is a liposome preparation suitable for use in the treatment of COVID-19.

SYSTEM, APPARATUS, AND METHOD FOR VIRAL MONITORING IN EFFLUENT

Resumen de: US20260266815A1

A system for viral monitoring in effluent includes at least one graphene-based field-effect transistor and circuitry, wherein the circuitry is configured to repeatedly monitor and determine presence of SARS-CoV-2 (COVID virus) in the effluent. The circuitry is configured to apply a gate voltage and measure a conductance across each of the at least one graphene-based field-effect transistor, compare the measured conductance across each of the at least one graphene-based field-effect transistor to a threshold conductance, and determine whether levels of the COVID virus exceed a predetermined threshold in the effluent. If levels of the COVID virus exceed the predetermined threshold in the effluent, the circuitry is configured to remove at least a portion of the bound COVID virus from the proteins of the at least one graphene-based field-effect transistor.

METHODS OF TREATING FIBROSIS

Resumen de: US20260263460A1

The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment.

PROTEIN AND VACCINE AGAINST INFECTION BY SARS-COV-2 OMICRON VARIANT STRAIN AND SUBTYPE THEREOF

Resumen de: US20260263587A1

The present invention relates to the field of medicines, and relates to a protein and vaccine for resisting infection from a SARS-COV-2 Omicron mutant strain and a subtype thereof. In order to solve the problem of lack of drugs for effective prevention and treatment for infections from the SARS-COV-2 Omicron mutant strain and the subtype thereof, the present invention provides the protein and the vaccine for resisting infection from the SARS-COV-2 Omicron mutant strain and the subtype thereof. The vaccine is optimally designed on the basis of an RBD sequence in an S protein of the SARS-COV-2 Omicron mutant strain and substrains BA.4/5, BQ.1.1, and XBB.1.5, can help a host to resist a coronavirus infection, and particularly has a relatively good prevention and treatment effect on a cross infection caused by a SARS-COV-2 Omicron mutant strain and subtype viruses thereof.

METHOD FOR TREATING COVID-19 INFECTION IN A HUMAN SUBJECT

Resumen de: US20260263510A1

0000 A method of treating a COVID-19 infection including administering to a subject in need thereof an effective amount of a composition, where the composition includes silica nanoparticles, superparamagnetic iron oxide nanoparticles (SPIONs), chitosan, cisplatin, ribavirin, and an angiotensin-converting enzyme 2 (ACE-2). The SPIONs and ACE-2 are dispersed on an outer surface of the silica nanoparticles. The chitosan at least partially wraps around the outer surface of the silica nanoparticles. The cisplatin and ribavirin are in pores of the silica nanoparticles. The particles of the composition are monodisperse, and spherical, and have an average diameter of 70-100 nanometers (nm).

MULTI-OMIC PROFILING SIGNATURES FOR COVID-19

Resumen de: US20260265825A1

0000 A signature for identifying a subject at risk of developing a severe reaction to a SARS-CoV virus by detecting one or more of elevated serum cytokines, reduced monocyte subclasses, differentially expressed genes in monocyte subclasses, differentially expressed gene in CD8+ effector memory T cells, and elevated chromatin accessibility in intermediate monocytes are disclosed herein. Also disclosed are methods for obtaining the signature, methods of identifying a subject at risk of developing a severe reaction to a SARS-CoV virus, and methods of treating COVID-19.

REAGENTS AND METHODS FOR PREVENTING, TREATING OR LIMITING SEVERE ACUTE RESPIRATORY SYNDROME (SARS) CORONAVIRUS INFECTION

Resumen de: US20260263588A1

Polypeptides and nucleic acids encoding the polypeptides are provided that include severe acute respiratory syndrome Co-V-2 (SARS-CoV-2) spike polypeptide receptor-binding domain (RBD) polypeptides that include at least one non-naturally occurring N-linked glycosylation motif in any of the residues 369-372, 388-390, 405-407, 417-419, 437-441, 477-479, 487-489 and 501-503, which are capable of multimerization and thus presenting multiple copies of the RBD to enhance the immune response generated when the polypeptide is administered to a subject.

METHODS OF TREATING FIBROSIS

Resumen de: AU2025233025A1

Described herein are methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment.

SARS-COV2 ANTIBODIES AND METHODS OF USE THEREOF

Resumen de: US20260265350A1

The present disclosure is directed to antibodies and antigen binding fragments thereof, having improved binding specificity for coronaviruses, such as SARS-CoV-2, including neutralizing antibodies. Other embodiments contemplate using anti-CoV-S antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with coronaviruses or the S protein thereof and conditions where neutralization or inhibition of coronaviruses or the S protein thereof would be therapeutically beneficial.

T CELL BROAD BETACORONAVIRUS VACCINE

Resumen de: WO2026185415A1

The present invention relates to polypeptides, polynucleotides, compositions, microorganisms, vectors and vaccine compositions optimised for the prophylactic or therapeutic treatment of an infection caused by Betacoronaviruses, including but not limited to: Embecovirus, Hibecovirus, Merbecovirus, Nobecovirus, Sarbecovirus, MERS-CoV, SARS-CoV-1 and SARS-CoV-2.

PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM

Resumen de: US20260263473A1

In alternative embodiments, provided are pharmaceutical compositions and therapeutic combinations of drugs, including products of manufacture and kits, for treating, preventing or ameliorating (for example, decreasing the symptoms of, or decreasing the mortality of) a viral infection, for example, a coronavirus infection such as a COVID-19 or variant thereof, and methods for making and using same. In alternative embodiments, provided are products of manufacture and kits for delivering pharmaceutical compositions and therapeutic combinations of drugs as provided herein, for example provided are transdermal delivery devices such as patches that can have multiple compartments for delivering transdermally different drugs at the same time.

TREATMENT OF HUMAN CORONAVIRUS INFECTIONS USING ALPHA-GLUCOSIDASE GLYCOPROTEIN PROCESSING INHIBITORS

Resumen de: US20260263430A1

The present invention concerns the use of an alpha-glucosidase glycoprotein processing inhibitor for the treatment or prevention of human coronavirus infections, such as SARS-CoV-2 or SARS-CoV-2 variant infections. Aspects of the invention include methods for treating or preventing coronavirus infection, or a symptom thereof, by administering an alpha-glucosidase glycoprotein processing inhibitor, such as castanospermine, or a pharmaceutically acceptable salt, derivative, or prodrug thereof, to a human subject; methods for inhibiting human coronavirus infection in a human cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing human coronavirus infection.

METHOD FOR PREPARING 4-(2-(DIFLUOROMETHOXY)PHENYL)-5-METHYLTHIAZOL-2-AMINE, WHICH EXHIBITS PREDICTED ACTIVITY AGAINST THE SARS-COV-2 VIRUS

Resumen de: UA164235U

Method for preparing 4-(2-(difluoromethoxy)phenyl)-5-methylthiazol-2-amine: , which exhibits predicted activity against the SARS-CoV-2 virus, according to which a mixture of equimolar amounts of 2-bromo-1-(2-(difluoromethoxy)phenyl)propan-1-one and thiourea is boiled for three hours in propan-2-ol, cooled, filtered and suspended in 50 ml of saturated NaHCO3 solution, stirred for 5 hours, filtered, washed with water, crystallized from propan-2-ol.

METHOD FOR DETERMINING THE LEVEL OF RISK OF SEVERE COVID-19 DISEASE IN A PATIENT

Nº publicación: EP4802102A1 09/09/2026

Solicitante:

PANSTWOWY INSTYTUT MEDYCZNY MINI SPRAW WEWNETRZNYCH I ADMINISTRACJI [PL]
BIOLAB GENETIC SP Z O O [PL]
Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych I Administracji
Biolab Genetic Sp. z o.o.

Resumen de: WO2025080149A1

A method for assaying the presence of two genetic polymorphisms whose occurrence significantly modifies the course of COVID-19 disease is disclosed. The genetic polymorphisms, namely rs143334143 locus and at the rs74956615. This method represents a new tool in the public health protection against COVID-19 disease.